Financial Performance - The company expects a net profit attributable to shareholders of between 15 million and 22 million yuan for 2024, compared to a loss of 184.91 million yuan in the same period last year[4]. - The net profit after deducting non-recurring gains and losses is projected to range from a loss of 5 million yuan to a profit of 2 million yuan, compared to a loss of 193.91 million yuan in the previous year[4]. - Non-recurring gains and losses are expected to impact net profit by approximately 18 million to 22 million yuan, primarily from government subsidies and investment income[7]. - The financial data presented is preliminary and subject to change upon final audit, with detailed figures to be disclosed in the 2024 annual report[8]. Business Strategy - The company has focused on its core business in food safety rapid testing and animal diagnostics, achieving revenue growth in both segments[6]. - International market expansion efforts have resulted in increased sales scale year-on-year, supported by investments in personnel, channel development, and product certification[6]. - The company has reduced costs significantly after strategically downsizing its in vitro diagnostics business, leading to improved profitability[7]. - The company is enhancing its market competitiveness by deepening its business layout in the food safety sector and investing in animal diagnostics and intelligent instruments[7].

证券时报e公司讯，企查查APP显示，近日，泉州安瑞中农科技发展有限公司成立，法定代表人为廖丁 菊，经营范围包含：人工智能应用软件开发；智能农业管理；人工智能行业应用系统集成服务等。 企查查股权穿透显示，该公司由易瑞生物等共同持股。 ...

| 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-001 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于 2024 年第四季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、证券代码：300942 证券简称：易瑞生物 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，深圳市易瑞生物技术 股份有限公司（以下简称"公司"）现将 2024 年第四季度可转换公司债券（以 下简称"可转债"）转股及公司总股本变化情况公告如下： 一、可转债基本情况 2、债券代码：123220 债券简称：易瑞转债 3、转股期限：2024 年 2 月 26 日至 2029 年 8 月 17 日 4、最新有效的转股价格：8.89 元/股 5、转股股份来源：新增股份 日起至可转债到期日止，即 2024 年 2 月 26 日至 2029 年 8 月 17 日。 （一）可转 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2024-088 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 本次质押股份不存在负担重大资产重组等业绩补偿义务。 2、股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 深圳市易瑞生物技术股份有限公司 关于公司实际控制人部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日收到公司实 际控制人朱海先生的通知，获悉朱海先生将其持有公司的部分股份办理了质押， 现将具体内容公告如下： 一、股东股份质押基本情况 1、本次股份质押基本情况 | 股东名称 | 是否为控股股 东或第一大股 东及其一致行 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起始 | 质押到期 | | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 数量 | 持 ...

投资者关系活动记录表 参与单位名称 参与公司 2024 年度深圳辖区上市公司集体接待日活动的投资 及人员姓名 者 证券代码：300942 证券简称：易瑞生物 编号：2024-009 债券代码：123220 债券简称：易瑞转债 深圳市易瑞生物技术股份有限公司 | --- | --- | --- | |--------------|----------------------|----------------------------------| | | 特定对象调研（线下） | 分析师会议 | | 投资者关系活 | 媒体采访 | 业绩说明会 | | 动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | 其他 2024 年度深圳辖区上市公 | | | 司集体接待日活动 | | | --- | --- | |---------------------------|--------------------------------------------------------------------------------------------------------------------------- ...

届时公司董事长、总经理肖昭理先生，董事、副总经理、董事会秘书李文天 女士，财务总监王广生先生将通过网络文字形式与投资者进行沟通交流，欢迎广 大投资者踊跃参与！ 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，深圳市易瑞生物技术股份有限公司 （以下简称"公司"）将参加由深圳证监局和深圳证券交易所指导、深圳上市公 司协会与深圳市全景网络有限公司联合举办的"2024 年度深圳辖区上市公司集 体接待日"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2024 年 12 月 12 日（周四）15:40-17:00。 | 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2024-087 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于参加 2024 年度 ...

深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2024年11月25 日、2024年11月26日、2024年11月27日连续3个交易日收盘价格涨幅偏离值累计 超过30%，根据深圳证券交易所的相关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 | 证券代码：300942 | 证券简称：易瑞生物 公告编号：2024-086 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 针对公司股票交易异常波动情况，公司董事会对公司、控股股东、实际控 制人等就有关事项进行了核实，现将有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司经营情况及内外部经营环境未发生重大变化； 1 四、风险提示 1、经自查，公司不存在违反公平信息披露规定的情形。 3、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 4、公司、控股股东和实际控 ...

Financial Performance - Revenue for Q3 2024 was CNY 54,399,597.05, an increase of 2.66% year-over-year, while year-to-date revenue decreased by 4.27% to CNY 158,047,893.25[2] - Net profit attributable to shareholders for Q3 2024 was CNY 5,456,465.06, representing a significant increase of 118.48% year-over-year, and year-to-date net profit increased by 103.93% to CNY 3,896,966.64[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was CNY -4,611,154.99, a decrease of 85.93% year-over-year, with year-to-date figures showing a decrease of 90.89% to CNY -9,870,233.57[2] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.0136, reflecting an increase of 118.45% year-over-year, with year-to-date figures at CNY 0.0097, up 103.92%[2] - The company reported a net loss of CNY 820,248.12 for the quarter, compared to a profit in the same quarter last year[16] - The net profit for Q3 2024 was CNY 2,987,228.32, a significant recovery from a net loss of CNY 99,216,611.87 in the same period last year, marking a turnaround of over 103%[17] - Operating profit reached CNY 5,067,489.74, compared to an operating loss of CNY 95,086,336.81 in Q3 2023, indicating a substantial improvement[17] - Total revenue from operating activities was CNY 183,656,359.44, down from CNY 202,566,641.66 year-on-year, reflecting a decrease of approximately 9.5%[19] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 16,031,477.88, an increase of 127.46% compared to the same period last year[2] - Cash flow from operating activities generated a net inflow of CNY 16,031,477.88, a recovery from a net outflow of CNY 58,388,800.99 in the previous year[20] - The company reported a significant increase in cash flow from investment activities, with a net outflow of CNY 315,617,017.17 compared to an inflow of CNY 89,427,377.77 in the previous year[20] - Cash and cash equivalents at the end of Q3 2024 amounted to CNY 250,473,992.19, a decrease from CNY 481,748,962.98 at the beginning of the period[13] Assets and Liabilities - Total assets as of the end of the reporting period were CNY 1,378,757,205.50, an increase of 1.65% from the end of the previous year[2] - Total assets as of September 30, 2024, were CNY 1,378,757,205.50, compared to CNY 1,356,339,278.93 at the start of the year, reflecting a slight increase[15] - Total liabilities increased to CNY 525,041,312.35 from CNY 507,611,047.32, indicating a rise of approximately 3.0%[15] - The company's equity attributable to shareholders rose to CNY 852,891,282.94 from CNY 848,993,883.06, a marginal increase[15] Operational Performance - The company's operating revenue for Q3 2024 was ¥158,047,893.25, a decrease of 4.27% compared to ¥165,099,285.79 in the previous period, primarily due to a contraction in the in vitro diagnostic business[8] - Operating costs decreased by 36.69% to ¥53,588,701.95 from ¥84,644,515.39, reflecting the reduction in the in vitro diagnostic business[8] - R&D expenses were reduced by 40.74% to ¥28,803,950.34 from ¥48,609,330.98, attributed to the contraction in the in vitro diagnostic business[8] - The company reported a significant increase in other income, which rose by 37.72% to ¥12,695,410.62 from ¥9,217,965.42, mainly due to increased government subsidies[8] - The fair value change income surged by 1368.51% to ¥2,233,169.07 from ¥152,070.07, driven by gains from financial products[8] - The company recorded a 63.44% decrease in tax refunds received, totaling ¥12,943,692.74 compared to ¥35,405,225.31 in the previous period[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,913[9] - The largest shareholder, 易瑞（海南）创业投资有限公司, holds 33.90% of the shares, totaling 135,901,179 shares[10] Future Outlook and Strategy - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[14] - The company plans to continue focusing on R&D and market expansion to drive future growth and profitability[17] Reporting and Compliance - The third quarter report of Shenzhen Yirui Biotechnology Co., Ltd. is unaudited[22] - The company will implement new accounting standards starting in 2024[21] - The board of directors released the third quarter report on October 28, 2024[22] - There are no specific financial performance metrics or user data provided in the report[22] - Future outlook and performance guidance details are not included in the current report[22] - Information regarding new product and technology development is absent from the report[22] - Market expansion and acquisition strategies are not discussed in the report[22] - Other new strategies are not mentioned in the third quarter report[22] - The report does not provide any specific numerical data or percentages related to performance[22] - The report confirms that it is the first execution of the new accounting standards for the year[21]

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2024-083 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 1、审议通过《关于公司 2024 年第三季度报告的议案》 本议案已经公司董事会审计委员会审议通过。 经审核，董事会认为：公司《2024 年第三季度报告》的编制和审核程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 7 票；反对 0 票；弃权 0 票。 《2024 年第三季度报告》详见巨潮资讯网（http://www.cninfo.com.cn）。 第三届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2024年10月28日 （星期一）在深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园公司 会议室以现场与通讯表决相结合的方式召开了第三届董事会第九次会议。本 ...

| 证券代码：300942 | 证券简称：易瑞生物 公告编号：2024-084 | | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | 深圳市易瑞生物技术股份有限公司 第三届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市易瑞生物技术股份有限公司（以下简称"公司"）于2024年10月28日 （星期一）在深圳市宝安区航城街道三围社区运昌路289号易瑞生物产业园公司 会议室以现场与通讯表决相结合的方式召开了第三届监事会第四次会议。本次会 议通知已于2024年10月25日以电子邮件、微信等方式送达全体监事。 本次会议由监事会主席莫秋华先生召集并主持，本次会议应出席监事3人， 实际出席监事3人；公司董事会秘书列席了本次会议。本次会议的召集、通知、 召开和表决程序均符合《公司法》等有关法律、行政法规、规范性文件、部门规 章及《公司章程》的有关规定，会议合法、有效。 1 二、监事会会议审议情况 经与会监事审议并以书面记名投票的方式对本次会议的议案进行了表决，审 议结果如下： 1、审议通 ...